The TOGETHER Project - Kidney RNA-seq Validation
Completed
- Conditions
- Kidney Transplant Rejection
- Registration Number
- NCT03874299
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The researchers are trying to develop a way to measure the risk of rejection through the validation of a blood test.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 302
Inclusion Criteria
- Adult (>/=18 years) renal transplant recipient.
- Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research.
Exclusion Criteria
-Adult (<18 years) renal transplant recipient.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To validate the use of a RNA-seq based peripheral blood assay in renal transplant recipients. 3 years The study will validate the ability of a peripheral blood assay to assess the risk of biopsy proven rejection.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does RNA-seq signature validation target in kidney transplant rejection detection?
How does the RNA-seq blood test in NCT03874299 compare to biopsy for predicting acute kidney transplant rejection?
Which gene expression biomarkers in NCT03874299 correlate with long-term kidney transplant outcomes?
What adverse events are associated with RNA-seq-based rejection monitoring in kidney transplant recipients?
Are there competing RNA-based biomarkers or diagnostics for kidney transplant rejection beyond the TOGETHER Project?
Trial Locations
- Locations (1)
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Mayo Clinic🇺🇸Rochester, Minnesota, United States